Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, van den Berg B, Doets AY, Leonhard SE, Verboon C, Huizinga R, Drenthen J, Arends S, Budde IK, Kleyweg RP, Kuitwaard K, van der Meulen MFG, Samijn JPA, Vermeij FH, Kuks JBM, van Dijk GW, Wirtz PW, Eftimov F, van der Kooi AJ, Garssen MPJ, Gijsbers CJ, de Rijk MC, Visser LH, Blom RJ, Linssen WHJP, van der Kooi EL, Verschuuren JJGM, van Koningsveld R, Dieks RJG, Gilhuis HJ, Jellema K, van der Ree TC, Bienfait HME, Faber CG, Lovenich H, van Engelen BGM, Groen RJ, Merkies ISJ, van Oosten BW, van der Pol WL, van der Meulen WDM, Badrising UA, Stevens M, Breukelman AJ, Zwetsloot CP, van der Graaff MM, Wohlgemuth M, Hughes RAC, Cornblath DR, van Doorn PA; Dutch GBS Study Group. Walgaard C, et al. Among authors: faber cg. Lancet Neurol. 2021 Apr;20(4):275-283. doi: 10.1016/S1474-4422(20)30494-4. Epub 2021 Mar 17. Lancet Neurol. 2021. PMID: 33743237 Clinical Trial.
Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis.
Badrising UA, Schreuder GM, Giphart MJ, Geleijns K, Verschuuren JJ, Wintzen AR, Maat-Schieman ML, van Doorn P, van Engelen BG, Faber CG, Hoogendijk JE, de Jager AE, Koehler PJ, de Visser M, van Duinen SG; Dutch IBM Study Group. Badrising UA, et al. Among authors: faber cg. Neurology. 2004 Dec 28;63(12):2396-8. doi: 10.1212/01.wnl.0000148588.15052.4c. Neurology. 2004. PMID: 15623710
Drug treatment for myotonia.
Trip J, Drost G, van Engelen BG, Faber CG. Trip J, et al. Among authors: faber cg. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD004762. doi: 10.1002/14651858.CD004762.pub2. Cochrane Database Syst Rev. 2006. PMID: 16437496 Free PMC article. Review.
Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study.
Garssen MP, van Koningsveld R, van Doorn PA, Merkies IS, Scheltens-de Boer M, van Leusden JA, van Schaik IN, Linssen WH, Visscher F, Boon AM, Faber CG, Meulstee J, Prick MJ, van den Berg LH, Franssen H, Hiel JA, van den Bergh PY, Sindic CJ. Garssen MP, et al. Among authors: faber cg. J Neurol Neurosurg Psychiatry. 2007 Sep;78(9):1012-3. doi: 10.1136/jnnp.2006.102731. J Neurol Neurosurg Psychiatry. 2007. PMID: 17702789 Free PMC article. Clinical Trial. No abstract available.
A natural history study of late onset spinal muscular atrophy types 3b and 4.
Piepers S, van den Berg LH, Brugman F, Scheffer H, Ruiterkamp-Versteeg M, van Engelen BG, Faber CG, de Visser M, van der Pol WL, Wokke JH. Piepers S, et al. Among authors: faber cg. J Neurol. 2008 Sep;255(9):1400-4. doi: 10.1007/s00415-008-0929-0. Epub 2008 Jun 30. J Neurol. 2008. PMID: 18575920
240 results